China’s Peijia Medical Ltd (HKG: 9996) announced the completion of the first two implant surgeries using its Trilogy transcatheter heart valve (THV) System for the treatment of severe aortic valve regurgitation in Taiwan.
Product Details
The Trilogy THV System, a proprietary transcatheter aortic valve replacement product with CE mark, is designed for patients with symptomatic severe aortic valve regurgitation or symptomatic severe aortic valve stenosis. It is intended for patients who have been determined by the cardiac team, including cardiac surgeons, to have a high risk of surgical aortic valve replacement surgery.-Fineline Info & Tech
Leave a Reply